PURPOSE: The brain is a common site of metastasis for patients with high-risk melanoma. Although surgery or stereotactic radiosurgery are highly effective local treatments for a small number of metastases, there is a high risk of developing additional brain metastases. The role of adjuvant whole-brain radiotherapy (WBRT) in reducing new metastases is controversial, with a lack of high-level evidence specifically for melanoma. METHODS: In this randomized phase III trial, patients who had local treatment of one to three melanoma brain metastases were randomly assigned to WBRT or observation. The primary end point was distant intracranial failure within 12 months, and secondary end points included time to intracranial failure, survival, and time to deterioration in performance status. RESULTS:Between April 2009 and September 2017, 215 patients were randomly assigned from 24 centers. Median follow-up was 48.1 months (range, 39.6 to 68 months). Forty-two percent of patients in the WBRT group and 50.5% of those in the observation developed distant intracranial failure within 12 months (odds ratio, 0.71; 95% CI, 0.41 to 1.23; P = .22) and the rates over the entire follow-up period were 52.0% and 57.9%, respectively (odds ratio, 0.79; 95% CI, 0.45 to 1.36; P = .39). Local failure rate was lower after WBRT (20.0% v 33.6%; P = .03). At 12 months, 41.5% of patients in the WBRT group and 51.4% of patients in the observation group had died (P = .28), with no difference in the rate of neurologic death. Median time to deterioration in performance status was 3.8 months after WBRT and 4.4 months with observation (P = .32). WBRT was associated with more grade 1 to 2 acute toxicity. CONCLUSION: After local treatment of one to three melanoma brain metastases, adjuvant WBRT does not provide clinical benefit in terms of distant intracranial control, survival, or preservation of performance status.
RCT Entities:
PURPOSE: The brain is a common site of metastasis for patients with high-risk melanoma. Although surgery or stereotactic radiosurgery are highly effective local treatments for a small number of metastases, there is a high risk of developing additional brain metastases. The role of adjuvant whole-brain radiotherapy (WBRT) in reducing new metastases is controversial, with a lack of high-level evidence specifically for melanoma. METHODS: In this randomized phase III trial, patients who had local treatment of one to three melanoma brain metastases were randomly assigned to WBRT or observation. The primary end point was distant intracranial failure within 12 months, and secondary end points included time to intracranial failure, survival, and time to deterioration in performance status. RESULTS: Between April 2009 and September 2017, 215 patients were randomly assigned from 24 centers. Median follow-up was 48.1 months (range, 39.6 to 68 months). Forty-two percent of patients in the WBRT group and 50.5% of those in the observation developed distant intracranial failure within 12 months (odds ratio, 0.71; 95% CI, 0.41 to 1.23; P = .22) and the rates over the entire follow-up period were 52.0% and 57.9%, respectively (odds ratio, 0.79; 95% CI, 0.45 to 1.36; P = .39). Local failure rate was lower after WBRT (20.0% v 33.6%; P = .03). At 12 months, 41.5% of patients in the WBRT group and 51.4% of patients in the observation group had died (P = .28), with no difference in the rate of neurologic death. Median time to deterioration in performance status was 3.8 months after WBRT and 4.4 months with observation (P = .32). WBRT was associated with more grade 1 to 2 acute toxicity. CONCLUSION: After local treatment of one to three melanoma brain metastases, adjuvant WBRT does not provide clinical benefit in terms of distant intracranial control, survival, or preservation of performance status.
Authors: Douglas Guedes de Castro; Carlos Henrique Andrade Teixeira; Guilherme Rocha Melo Gondim; Patrícia Bailão Aguilar; Marcos André de Sá Barreto Costa; Thiago William Carnier Jorge; Rodrigo de Morais Hanriot Journal: Clin Transl Oncol Date: 2022-05-11 Impact factor: 3.340
Authors: Cátia Monteiro; Lauritz Miarka; María Perea-García; Neibla Priego; Pedro García-Gómez; Laura Álvaro-Espinosa; Ana de Pablos-Aragoneses; Natalia Yebra; Diana Retana; Patricia Baena; Coral Fustero-Torre; Osvaldo Graña-Castro; Kevin Troulé; Eduardo Caleiras; Patricia Tezanos; Pablo Muela; Elisa Cintado; José Luis Trejo; Juan Manuel Sepúlveda; Pedro González-León; Luis Jiménez-Roldán; Luis Miguel Moreno; Olga Esteban; Ángel Pérez-Núñez; Aurelio Hernández-Lain; José Mazarico Gallego; Irene Ferrer; Rocío Suárez; Eva M Garrido-Martín; Luis Paz-Ares; Celine Dalmasso; Elizabeth Cohen-Jonathan Moyal; Aurore Siegfried; Aisling Hegarty; Stephen Keelan; Damir Varešlija; Leonie S Young; Malte Mohme; Yvonne Goy; Harriet Wikman; Jose Fernández-Alén; Guillermo Blasco; Lucía Alcázar; Clara Cabañuz; Sergei I Grivennikov; Andrada Ianus; Noam Shemesh; Claudia C Faria; Rebecca Lee; Paul Lorigan; Emilie Le Rhun; Michael Weller; Riccardo Soffietti; Luca Bertero; Umberto Ricardi; Joaquim Bosch-Barrera; Elia Sais; Eduard Teixidor; Alejandro Hernández-Martínez; Alfonso Calvo; Javier Aristu; Santiago M Martin; Alvaro Gonzalez; Omer Adler; Neta Erez; Manuel Valiente Journal: Nat Med Date: 2022-04-11 Impact factor: 87.241
Authors: John H Suh; Rupesh Kotecha; Samuel T Chao; Manmeet S Ahluwalia; Arjun Sahgal; Eric L Chang Journal: Nat Rev Clin Oncol Date: 2020-02-20 Impact factor: 66.675
Authors: Michael T Milano; Veronica L S Chiang; Scott G Soltys; Tony J C Wang; Simon S Lo; Alexandria Brackett; Seema Nagpal; Samuel Chao; Amit K Garg; Siavash Jabbari; Lia M Halasz; Melanie Hayden Gephart; Jonathan P S Knisely; Arjun Sahgal; Eric L Chang Journal: Neuro Oncol Date: 2020-12-18 Impact factor: 12.300
Authors: Roshan S Prabhu; Brandon E Turner; Anthony L Asher; Samuel R Marcrom; John B Fiveash; Paul M Foreman; Robert H Press; Zachary S Buchwald; Walter J Curran; Kirtesh R Patel; William G Breen; Paul D Brown; Krishan R Jethwa; Inga S Grills; Jessica D Arden; Lauren M Foster; Matthew A Manning; Zachary K Vaslow; Stuart H Burri; Scott G Soltys Journal: Adv Radiat Oncol Date: 2021-01-08